Search Results
Your search for ,UsE matches 11246 pages
Showing 10001 - 10050Coriolus versicolor
The use of dietary supplements by patients with cancer has increased significantly over the past 20 years despite insufficient evidence of safety and effectiveness. Finding reliable sources of information about dietary supplements can be daunting. Patients typically rely on family, friends, and the ...
‘Share the Journey’ Mobile App Aims to Understand the Different Experiences of Breast Cancer Survivors
In March 2015, Sage Bionetworks and Apple released “Share the Journey: Mind, Body, and Wellness After Breast Cancer,” a patient-centered iPhone app that tracks five common consequences of breast cancer treatment, including fatigue, cognitive function, sleep disturbances, mood changes, and a...
A Cancer Handbook for Inquisitive Laypersons and Health-Care Professionals
Bookmark Title: The Cancer Solution: Taking Charge of Your Life With CancerAuthor: Jack C. Westman, MD, MSPublisher: Archway PublishingPublication date: January 15, 2015Price: $20.00; paperback, 310 pages I was at a meeting in San Francisco in 1978 and received a call from my wife, Nancy:...
How Carolyn D. Runowicz, MD, FASCO, Is Shaping the Future of Gynecologic Cancers
Carolyn D. Runowicz, MD, FASCO, has worn just about every hat in the field of oncology—clinician, professor, researcher, administrator, and even cancer survivor. Currently the Executive Associate Dean for Academic Affairs and Professor in the Department of Obstetrics and Gynecology at the Herbert ...
The Flipped Classroom: Swapping the Traditional Lecture Hall for an Online Version
Despite enormous advances in modern medicine and the explosion of biomedical information over the past century, the way medical education is taught in the United States is stuck in a format that does not optimize learning, according to Charles Prober, MD, Senior Associate Dean for Medical Education ...
Access to Cancer Medicines Not Uniform Across Europe
Access to cancer medicines—including some old standbys—is inconsistent across Europe, depriving many patients of treatments that are the standard of care elsewhere,1 according to Alexandru E. Eniu, MD, PhD, Chair of the European Society for Medical Oncology (ESMO) Emerging Countries Committee and...
COMBI-d Trial and the Need to Guide Progress in Melanoma Treatment
As reviewed in this issue of The ASCO Post, Long et al1 have reported the final overall survival analysis of the COMBI-d phase III trial comparing combination therapy with the BRAF inhibitor dabrafenib (Tafinlar) and the MEK inhibitor trametinib (Mekinist) to monotherapy with dabrafenib alone,...
ASCO Guidelines: A Collaborative Effort
The ASCO Guidelines Program has worked with other professional societies and guideline development organizations in an effort to expand the ASCO guideline portfolio and harmonize recommended care options across prominent guideline development groups. For ASCO, this effort began with a systematic...
Roswell Park Cancer Institute Partners With Cuban Scientists to Develop Lung Cancer Vaccine
Just 4 months after President Barack Obama’s announcement in December 2014 that there would be an easing of the trade embargo between the United States and Cuba, a deal was struck between Roswell Park Cancer Institute in Buffalo, New York, and the Center for Molecular Immunology (CIM) in Havana,...
State-of-the-Art Management of Germ Cell Tumors Produces High Cure Rates
Pasquale W. Benedetto, MD, the Leonard M. Miller Professor of Medicine at the University of Miami/Sylvester Comprehensive Cancer Center, recently spoke at the 2015 New Orleans Summer Cancer Meeting about his approach to diagnosing and treating germ cell tumors in men.1 The ASCO Post was there to...
Genetic Testing in Breast Cancer Offers Much Information but Poses Challenges in Interpretation
For breast cancer patients with robust family histories, medical oncologists should be testing not only for BRCA1/2 mutations, but also for large duplications and deletions as well as for PALB2 mutations. “These [findings] have proven utility in testing breast cancer patients,” said Louise E....
NCI and Sage Bionetworks Present: Up for A Challenge?
The National Cancer Institute (NCI) Division of Cancer Control and Population Sciences is partnering with Sage Bionetworks for “Up for a Challenge (U4C): Stimulating Innovation in Breast Cancer Genetic Epidemiology.” This prize competition aims to explore the genomic basis of breast cancer in...
New Techniques in Oncologic Surgery and Radiology: Some Worth the Expense, Some Not So Much
In recent years, patients with cancer have had the benefit of much high technology: proton-beam radiotherapy, intensity-modulated radiation therapy, various minimally invasive surgery techniques, and robots in the operating room. They all receive hype in the professional and public press, and...
Brentuximab Vedotin for Consolidation Therapy in High-Risk Hodgkin Lymphoma
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On August 17, 2015, brentuximab vedotin (Adcetris) was approved...
Coping With Aging and Cancer: Psychosocial Factors and Geriatric-Specific Interventions
You can’t control the wind, but you can adjust your sails,” said Mindy Greenstein, PhD, consulting psychologist and author, to begin her talk at the 2015 World Congress of Psycho-Oncology, held in July in Washington, DC. The sense of this proverb pervaded the entire session on cancer and aging....
International Psycho-Oncology Society and American Psychosocial Oncology Society Meet to Foster Psychosocial Oncology Worldwide
The International Psycho-Oncology Society (IPOS) has partnered with the American Psychosocial Oncology Society (APOS) for the 17th World Congress of Psycho-Oncology, held in late July 2015 in Washington, DC. Its theme, “From National to Global: Implementing the Standard of Psychosocial Care in...
Role of Surgery and Adjuvant Radiotherapy in the Treatment of Breast Cancer Explored
Two separate retrospective studies have further refined our understanding of the respective contributions of surgery and radiotherapy in the treatment of breast cancer. However, these studies are not definitive, and “gold standard” trials are needed to arrive at definitive recommendations. Both...
Secondary Prevention in Metastatic Colorectal Cancer: Benefits of Vitamin D and Aspirin Explored
Two low-cost, low-tech options may lead to a survival benefit in metastatic colorectal cancer, according to separate retrospective studies selected for the Best of ASCO® 2015. The first study suggested that vitamin D supplementation is worthy of investigation in this regard,1 and the second study...
Colorectal Liver Metastases: Thumbs Up for Radiofrequency Ablation, Jury Still Out for Selective Internal Radiotherapy
Two “firsts” in studies of colorectal liver metastases were highlighted at the 2015 ASCO Annual Meeting: the first prospective randomized trial to evaluate radiofrequency ablation plus chemotherapy1 and the first large randomized phase III trial to study liver-directed selective internal radiation...
Indolent Lymphoma: A More Complex Malignancy Than Once Thought
With a growing number of options for follicular lymphoma, clinicians may wonder whether there is one best regimen. James O. Armitage, MD, FACP, FRCP, Professor of Medicine at the University of Nebraska, Omaha—and Editor-in-Chief of The ASCO Post—tackled this question and offered recommendations at...
Positioning Targeted and Immunotherapy-Based Approaches in Lung Cancer
With immunotherapy changing the face of lung cancer, is there still a place for targeted therapy? Two experts from Emory University debated this issue at the 2015 Debates and Didactics in Hematology and Oncology Conference held in Sea Island, Georgia. Fadlo Khuri, MD, was recently named President...
Charting a New Course: From Clinical Investigator to University President
What first intrigued Fadlo R. Khuri, MD, FACP, about the prospect of becoming the 16th President of the American University of Beirut (AUB) in Lebanon was the chance to give back to an institution and a country that had given him so much. Born in Boston, Massachusetts, in 1963, Dr. Khuri was raised ...
Our Patients Are the True Heroes of Cancer Research
A few weeks ago, I read an op-ed1 in The New York Times written by Stan Collender, a patient with Merkel cell carcinoma, a rare and aggressive type of skin cancer. In his article, he described his participation in a clinical trial for a new drug he is hoping will stem progression of his cancer and...
Elotuzumab Ushers in a New Era in Myeloma Therapy
The long wait for monoclonal antibodies for the treatment of multiple myeloma is over. In the landmark ELOQUENT-2 study, reviewed in this issue of The ASCO Post, Lonial and colleagues convincingly demonstrate the effectiveness of elotuzumab, a monoclonal antibody directed against SLAMF7, in the...
Internationally Acclaimed Cancer Researcher, Gianni Bonadonna, MD, Dies at 81
Gianni Bonadonna, MD, was considered the “Father of Italian Oncology,” but his scientific contributions to the field and his generous collegial spirit extended far beyond the shores of his native land. Dr. Bonadonna was at the forefront in the battle to convince the surgical establishment that...
ASCO Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility
As reported in the Journal of Clinical Oncology by Mark E. Robson, MD, of Memorial Sloan Kettering Cancer Center, and colleagues, ASCO has issued a policy statement update on genetic and genomic testing for cancer susceptibility.1 The statement, commissioned by ASCO’s Cancer Prevention and Ethics...
An Unvarnished, Behind-the-Scenes Look at the Hospital Nurse
BOOKMARK Title: The Nurses: A Year of Secrets, Drama, and Miracles With the Heroes of the HospitalAuthor: Alexandra RobbinsPublisher: Workman Publishing CompanyPublication date: April 14, 20155Price: $17.53; hardcover, 368 pages Florence Nightingale, the most famous and influential figure in...
Why It Is Important to Have a Physiatrist on a Cancer Care Team
Physical medicine and rehabilitation in oncology care explores the benefits of cancer rehabilitation in oncology clinical practice to screen survivors for physical and cognitive impairments along the care continuum to minimize survivors’ disability and maximize their quality of life. According to a ...
ASCO 2015: Geriatric Oncology Highlights
The theme of the 2015 ASCO Annual Meeting, Illumination and Innovation, is especially appropriate as we consider the field of geriatric oncology. For too long, the elderly cancer patient has remained in the dark regarding treatment planning, clinical trial enrollment, and shared decision-making....
Statin Use at Start of Androgen-Deprivation Therapy Increases Time to Progression During Treatment of Prostate Cancer
Statin use has been associated with improved outcomes in prostate cancer. In a study reported in JAMA Oncology, Lauren C. Harshman, MD, of Dana-Farber Cancer Institute, Boston, and colleagues found that statin use at the time of the initiation of androgen-deprivation therapy was associated with...
Updated Analysis of Menopausal Hormone Therapy and Breast Cancer Risk
As reviewed in this issue of The ASCO Post, Chlebowski and colleagues1 reported differing patterns of breast cancer risk during or after hormonal therapy with estrogen plus progestin2 or estrogen alone,3 in an analysis of two Women’s Health Initiative (WHI) trials. This recent update on risk...
Differing Patterns of Breast Cancer Risk After Hormone Therapy With Estrogen Plus Progestin or Estrogen Alone
In an analysis of Women’s Health Initiative trials reported in JAMA Oncology, Rowan T. Chlebowski, MD, PhD, of Harbor-UCLA Medical Center, and colleagues found differing patterns of breast cancer risk among women receiving menopausal hormone therapy with estrogen plus progestin or estrogen alone.1...
ASCO University® Releases 2015 Curricula for Advanced Practice Providers (ACAPP™)
ASCO University has released an updated version of ASCO’s Curricula for Advanced Practice Providers (ACAPP™). This popular series assists with the orientation of advanced practice providers (APPs) into oncology practices—a growing need as increasing numbers of APPs are hired to meet the demand for...
Lurie Cancer Center Receives $11.7 Million NCI Grant to Improve Treatment Using Nanotechnology
Northwestern University has received a 5-year, $11.7 million grant from the National Cancer Institute (NCI) to use nanotechnology to develop next-generation cancer treatments. With NCI support, the new Northwestern University Center for Cancer Nanotechnology Excellence (Northwestern CCNE) will use...
FDA Approves Rolapitant for Prevention of Chemotherapy-Induced Nausea and Vomiting
The U.S. Food and Drug Administration (FDA) approved rolapitant (Varubi) to prevent delayed-phase chemotherapy-induced nausea and vomiting. Rolapitant is approved in adults in combination with other antiemetic agents that prevent nausea and vomiting associated with initial and repeat courses of...
ASTRO Awards Seven Physician-Researchers $675,000 in Grants for Radiation Oncology Research
The American Society for Radiation Oncology (ASTRO) has selected seven leading physician-researchers to receive a total of $675,000 in awards and grants to advance radiation oncology research. Together, the grants will support studies in cancer biology, radiation physics, translational research,...
Radiation Oncology Looks to Collaboration for Big Data Systems
Radiation oncologists dream of a day when, faced with a new patient sitting in their office, they can quickly consult a computer database offering specific treatment recommendations based on accurate, freshly updated data from millions of previously treated patients with cancer. To hasten that day, ...
Managing High-Risk Patients With Febrile Neutropenia
Febrile neutropenia is of particular concern in high-risk patients who have undergone stem cell transplant, according to William J. Hogan, MB, BCh, Assistant Professor of Medicine at the Mayo Clinic in Rochester, Minnesota. Dr. Hogan delivered an update on febrile neutropenia management in this...
Rolapitant for Prevention of Delayed Chemotherapy-Induced Nausea and Vomiting
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On September 2, 2015, rolapitant (Varubi) was approved for use in...
HPV-Positive Head and Neck Cancer: When Can Chemotherapy Be Omitted?
Are there patients with locally advanced squamous cell carcinoma of the head and neck associated with human papillomavirus (HPV) for whom chemotherapy can be omitted? Experts debated this question at the 2015 Debates and Didactics in Hematology and Oncology Conference in Sea Island, Georgia,...
NCI Awards SPORE Grant to Mayo Clinic Multiple Myeloma Research Team
A team of Mayo Clinic Cancer Center scientists has been awarded a Specialized Program of Research Excellence (SPORE) grant in multiple myeloma from the National Cancer Institute. The Center is one of only three cancer centers to receive a SPORE grant for multiple myeloma cancer research. “With...
Mantle Cell Lymphoma: Is Transplantation Still Necessary?
Autologous stem cell transplantation has played a critical role in the treatment of mantle cell lymphoma, but in the age of novel treatments, is it always warranted? Two experts in the field explored the question at the 2015 Debates and Didactics in Hematology and Oncology Conference sponsored by...
ASCO Statement Addresses Recommendations for Obesity Clinical Trials in Cancer Survivors
As reported in the Journal of Clinical Oncology by Jennifer A. Ligibel, MD, of Dana-Farber Cancer Institute, and colleagues, ASCO has issued a statement providing recommendations for obesity clinical trials in cancer survivors.1 ASCO convened the Research Summit on Advancing Obesity Clinical...
Making Their Voices Heard: 118 Oncologists Speak Out About Stemming the High Cost of Cancer Drugs
In a bold move to shed light on the ramifications of the ever-increasing cost of cancer drugs for patients with cancer and for the health-care system, 118 prominent oncologists came together to write a commentary in Mayo Clinic Proceedings detailing their concerns.1 To learn more about these...
Our Children’s Future Is Our Responsibility
Cancer prevention is a child-care issue. With many of cancer’s instigators planting their seeds during childhood, we—as a profession and as a nation—must seize this important window of opportunity to protect the health and well-being of future generations. Current estimates suggest that up to...
First-Line Nivolumab/Ipilimumab Combination in Non–Small Cell Lung Cancer Shown to Be Tolerable
For advanced non–small cell lung cancer (NSCLC), first-line treatment with combined immune checkpoint blockade—in novel doses and schedules—was associated with deep and durable responses, encouraging progression-free survival, and much better tolerability than has been previously observed with...
Diagnosis of Additional Small Cancers Suggests Screening Mammography Leads to Overdiagnosis
A study of screening mammography across U.S. counties found that “the clearest result of mammography screening is the diagnosis of additional small cancers” but without a “concomitant decline in the detection of larger cancers, which might explain the absence of any significant difference in the...
Measuring Global Health Issues, Seven Billion Times
BOOKMARK Title: Epic Measures: One Doctor. Seven Billion PatientsAuthor: Jeremy N. SmithPublisher: Harper WavePublication date: April 7, 2015Price: $26.99; hardcover, 352 pages Health measures are essential tools in assessing public health and safety. Collecting large amounts of data is a laborious ...
Expect Questions About Treatment for Ductal Carcinoma in Situ
The recent study findings that women diagnosed with ductal carcinoma in situ had a low breast cancer–specific mortality and that preventing ipsilateral recurrences did not prevent breast cancer mortality1 might lead some women diagnosed with ductal carcinoma in situ to question the need for...
Varied Reactions to Study Finding That Preventing Ipsilateral Recurrence Did Not Prevent Death From Breast Cancer
Women diagnosed with ductal carcinoma in situ have a low risk of dying of breast cancer, according to an observational study looking at data from 108,196 women diagnosed with ductal carcinoma in situ between 1988 and 2011.1 The breast cancer–specific mortality rate for these women was 1.1% at 10...
